Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
emdgroup.com

See what CB Insights has to offer

Investments

8

Portfolio Exits

5

Partners & Customers

10

Service Providers

1

About Merck KGaA

Merck Group (FWB: MRK), aka Merck KGaA, is a science and technology company in the healthcare, life science, and performance materials businesses. The company develops biopharmaceutical therapies to treat cancer or multiple sclerosis, systems for scientific research and production, liquid crystals for smartphones and LCD televisions and more. Its former subsidiary Merck & Co. (NYSE: MRK) is a separate independent company.

Merck KGaA Headquarter Location

Frankfurter Strasse 250

Darmstadt, 64293,

Germany

+49 (0) 6151 72-0

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Merck KGaA

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Merck KGaA in 3 Expert Collections, including Conference Exhibitors.

C

Conference Exhibitors

5,302 items

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Merck KGaA Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Merck KGaA Rank

Research containing Merck KGaA

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Merck KGaA in 1 CB Insights research brief, most recently on Oct 9, 2019.

Latest Merck KGaA News

08:00 EDT MilliporeSigma Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 A...

Aug 9, 2022

News provided by Share this article Enables biopharmaceutical companies to increase the speed to clinical manufacturing Adds to company's best-in-class VirusExpress® Lentiviral Production Platform BURLINGTON, Mass., Aug. 9, 2022 /CNW/ -- MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has launched the VirusExpress® 293 Adeno-Associated Virus (AAV) Production Platform , making it one of the first CDMOs and technology-developers to provide a full viral vector manufacturing offering including AAV, Lentiviral, CDMO, CTO, and process development. This new platform enables biopharmaceutical companies to increase the speed to clinical manufacturing while reducing process development time and costs. MilliporeSigma scientists operating a 200 L Mobius® Single-Use Bioreactor using the VirusExpress® 293 Adeno-Associated Virus Production Platform at the company's facility in Carlsbad, California. "Cell and gene therapies offer the potential for curative treatments and can be commercialized in half the time compared to traditional therapies," said Dirk Lange, Head of Life Science Services, Life Science business sector of Merck KGaA, Darmstadt, Germany. "By increasing dose yields and dramatically reducing process development time, our VirusExpress® 293 AAV Production Platform will accelerate manufacturing of these therapies, ultimately delivering lifesaving treatments to patients faster." The new platform is an extension of the company's VirusExpress® offering, which can reduce process development time by up to 40 percent, based on MilliporeSigma's experience as a CDMO. The company's VirusExpress® Lentiviral Production Platform has enabled customers to increase the speed to clinical manufacturing, achieve five times higher titer than the leading competitor, and transition a legacy process to a templated solution. MilliporeSigma's VirusExpress® Platforms offer a simplified upstream workflow for the production of AAV and Lentivirus, making processes easier to manage, adjust and scale. In addition to accelerating process development, the suspension culture format allows for larger batch yields to enable more patient doses. Additionally, suspension culture is amenable to scalable robust manufacturing processes, while being less labor-intensive. The chemically defined cell culture media eliminates the safety, regulatory and supply chain concerns related to animal- and human-derived materials. Flexible licensing allows companies to manufacture vectors by using MilliporeSigma's contract manufacturing capabilities and expertise with access to both the upstream and downstream templates or by using in-house development or a third-party. MilliporeSigma is a leading CDMO and has been involved in this space since clinical trials for gene therapy began in the 1990s. In October 2021, the company opened its second Carlsbad, California-based facility, more than doubling its existing production capacity to support large-scale commercial manufacturing. Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn . All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service. About the Life Science business of Merck KGaA, Darmstadt, Germany  The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 26,000 employees and 55 manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics. Around 60,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck KGaA, Darmstadt, Germany generated sales of € 19.7 billion in 66 countries. The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com . SOURCE MilliporeSigma

Merck KGaA Investments

8 Investments

Merck KGaA has made 8 investments. Their latest investment was in Domain Therapeutics as part of their Milestone Payment on May 5, 2020.

CBI Logo

Merck KGaA Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/6/2020

Milestone Payment

Domain Therapeutics

Yes

1

11/20/2018

Corporate Minority

Subscribe to see more

Subscribe to see more

10

1/11/2011

Series A

Subscribe to see more

$99M

Subscribe to see more

10

2/22/2008

Series C

Subscribe to see more

$99M

Subscribe to see more

0

1/17/2008

Corporate Minority - II

Subscribe to see more

Subscribe to see more

10

Date

5/6/2020

11/20/2018

1/11/2011

2/22/2008

1/17/2008

Round

Milestone Payment

Corporate Minority

Series A

Series C

Corporate Minority - II

Company

Domain Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

0

10

Merck KGaA Portfolio Exits

5 Portfolio Exits

Merck KGaA has 5 portfolio exits. Their latest portfolio exit was Amnis Corporation on October 18, 2018.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/18/2018

Acquired - II

$99M

2

4/19/2018

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

2/1/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/28/2010

Acquired - II

Subscribe to see more

$99M

Subscribe to see more

10

6/2/2005

Spinoff / Spinout

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/18/2018

4/19/2018

2/1/2018

10/28/2010

6/2/2005

Exit

Acquired - II

Divestiture

IPO

Acquired - II

Spinoff / Spinout

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Merck KGaA Acquisitions

33 Acquisitions

Merck KGaA acquired 33 companies. Their latest acquisition was Exelead on January 06, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/6/2022

$99M

Acquired

17

1/7/2021

$99M

Acquired

3

7/1/2020

$99M

Acquired

1

10/7/2019

Subscribe to see more

$99M

Subscribe to see more

10

9/20/2019

Series E+

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

1/6/2022

1/7/2021

7/1/2020

10/7/2019

9/20/2019

Investment Stage

Series E+

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$99M

Note

Acquired

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

17

3

1

10

10

Merck KGaA Partners & Customers

10 Partners and customers

Merck KGaA has 10 strategic partners and customers. Merck KGaA recently partnered with Micron on August 8, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

8/3/2022

Partner

Japan

Merck KGaA, Darmstadt, Germany and Micron join forces for more sustainable gas solutions in the semiconductor industry

Merck KGaA , Darmstadt , Germany and Micron Technology , Inc. look back on a long-standing , trusted business relationship .

1

7/13/2022

Partner

United States

2

6/2/2022

Licensee

South Korea

1

6/1/2022

Partner

South Korea

Subscribe to see more

Subscribe to see more

10

5/22/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

8/3/2022

7/13/2022

6/2/2022

6/1/2022

5/22/2022

Type

Partner

Partner

Licensee

Partner

Partner

Business Partner

Country

Japan

United States

South Korea

South Korea

United States

News Snippet

Merck KGaA, Darmstadt, Germany and Micron join forces for more sustainable gas solutions in the semiconductor industry

Merck KGaA , Darmstadt , Germany and Micron Technology , Inc. look back on a long-standing , trusted business relationship .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

1

10

10

Merck KGaA Service Providers

1 Service Provider

Merck KGaA has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Lead Financial Advisor, Financial Advisor

Service Provider

Associated Rounds

Acq - P2P

Provider Type

Investment Bank

Service Type

Lead Financial Advisor, Financial Advisor

Partnership data by VentureSource

Merck KGaA Team

28 Team Members

Merck KGaA has 28 team members, including current Chief Executive Officer, Belén Garijo.

Name

Work History

Title

Status

Belén Garijo

Chief Executive Officer

Current

Aviv Sagi

Chief Financial Officer

Current

Gerhard Klaus

Chief Operating Officer

Current

Laura Matz

Chief Technology Officer

Current

Jan Adams

EMBL, and EMBL Ventures

Senior Director

Current

Name

Belén Garijo

Aviv Sagi

Gerhard Klaus

Laura Matz

Jan Adams

Work History

EMBL, and EMBL Ventures

Title

Chief Executive Officer

Chief Financial Officer

Chief Operating Officer

Chief Technology Officer

Senior Director

Status

Current

Current

Current

Current

Current

You May Also Like

L
Luminary Therapeutics

Luminary Therapeutics is a biotechnology company based in Minneapolis, Minnesota.

G
GI Innovation

GI Innovation is a bio-venture company that explores the development of new drugs through the combination of microbiome (human microorganism) and protein drugs.

T
Theracell Advanced Biotechnology

Theracell Advanced Biotechnology provides personalized and precision medicine, enabling individualized treatment with improved outcome. It offers advanced therapy medicinal products (ATMP), which are comprised of gene therapy, somatic cell therapy, and tissue engineered products. Based on viable cells or tissues, their pharmacological, immunologic or metabolic action should be considered as the principal mode of action. The company's therapeutic portfolio spans the areas of orthopedics, dermatology, nephrology, immuno-oncology, and tissue repair and regeneration. Through strategic partnerships Theracell Advanced Biotechnology participates in the global vision of the realization of personalized medicine tailored to individual patient needs.

XACT Robotics Logo
XACT Robotics

XACT Robotics develops a platform for robotic needle steering in minimally invasive interventional procedures such as biopsies and ablations.

Essentium Logo
Essentium

Essentium is a provider of 3D printing solutions for industrial additive manufacturing.

C
Cyfuse Biomedical

Cyfuse Biomedical is focused on the development, manufacturing, and sales of regenerative medicine-related products. The company aims to contribute to the medical fields of regenerative medicine and drug discovery by generating steric tissues and organs. The company has developed Regenova, a 3D bioprinter.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.